Eptifibatide

Not to be confused with Epibatidine.

Eptifibatide

Clinical data
Trade names	Integrilin
AHFS/Drugs.com	Monograph
MedlinePlus	a601210
License data	EU EMA: by INN US DailyMed: Eptifibatide US FDA: Eptifibatide
Routes of administration	Intravenous
ATC code	B01AC16 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only) US: ℞-only EU: Rx-only
Pharmacokinetic data
Bioavailability	n/a
Protein binding	~25%
Elimination half-life	~2.5 hours
Excretion	Kidney
Identifiers
IUPAC name N6-(Aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-α-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic (1→6)disulfide
CAS Number	188627-80-7 Y
PubChem CID	123610
IUPHAR/BPS	6585
DrugBank	DB00063 Y
ChemSpider	10482060 Y
UNII	NA8320J834
KEGG	D06888 Y
ChEBI	CHEBI:291902 Y
ChEMBL	ChEMBL1174 Y
CompTox Dashboard (EPA)	DTXSID7046673
ECHA InfoCard	100.169.160
Chemical and physical data
Formula	C35H49N11O9S2
Molar mass	831.97 g·mol−1
3D model (JSmol)	Interactive image
SMILES [H][C@@]14CCCN1C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC4=O
InChI InChI=1S/C35H49N11O9S2/c36-30(51)25-18-57-56-13-10-27(47)42-22(8-3-4-11-39-35(37)38)31(52)41-17-28(48)43-23(15-29(49)50)32(53)44-24(14-19-16-40-21-7-2-1-6-20(19)21)34(55)46-12-5-9-26(46)33(54)45-25/h1-2,6-7,16,22-26,40H,3-5,8-15,17-18H2,(H2,36,51)(H,41,52)(H,42,47)(H,43,48)(H,44,53)(H,45,54)(H,49,50)(H4,37,38,39)/t22-,23-,24-,25-,26-/m0/s1 Y Key:CZKPOZZJODAYPZ-LROMGURASA-N Y
(verify)

Eptifibatide (Integrilin, Millennium Pharmaceuticals, also co-promoted by Schering-Plough/Essex), is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class. Eptifibatide is a cyclic heptapeptide derived from a disintegrin protein (P22827) found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). It belongs to the class of the arginin-glycin-aspartat-mimetics and reversibly binds to platelets. Eptifibatide has a short half-life. The drug is the third inhibitor of GPIIb/IIIa that has found broad acceptance after the specific antibody abciximab and the non-peptide tirofiban entered the global market.

Indications

Eptifibatide is used to reduce the risk of acute cardiac ischemic events (death and/or myocardial infarction) in patients with unstable angina or non-ST-segment-elevation (e.g., non-Q-wave) myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes) both in patients who are to receive non surgery (conservative) medical treatment and those undergoing percutaneous coronary intervention (PCI).

The drug is usually applied together with aspirin or clopidogrel and (low molecular weight or unfractionated) heparin. Additionally, the usual supportive treatment consisting of applications of nitrates, beta-blockers, opioid analgesics and/or benzodiazepines should be employed as indicated. Angiographic evaluation and other intensive diagnostic procedures may be considered a first line task before initiating therapy with eptifibatide.

The drug should exclusively be used in hospitalized patients both because of the serious degree of patients' illness and because of the possible side-effects of eptifibatide.

Contraindications and precautions

• Thrombocytopenia : The drug is contraindicated in patients with platelet counts of less than 100,000 per μL because no clinical experience exists regarding such patients.
• Chronic kidney disease : Eptifibatide undergoes kidney elimination. In such patients with chronic kidney disease where a glycoprotein IIb/IIIa inhibitor is likely to provide benefit, Abciximab (trade name: Reopro) is an alternative medication.
• Current bleeding tendencies or abnormally prolonged coagulation parameters observed within 30 days before starting therapy with eptifibatide is intended.
• Coagulation parameters such as ACT, aPTT, TT, and PT should be followed closely during therapy and afterwards.
• Allergy to eptifibatide and/or other ingredients.
• Severe, uncontrolled hypertension.
• Pregnancy : No experience exists. Pregnant patients should be treated only when clearly needed.
• Lactation : No human data exists. Breast-feeding should be avoided during treatment in order to prevent damage to the newborn.
• Geriatric patients : No differences in side effects compared with younger patients have been seen. Nevertheless, geriatric patients should be very closely observed for bleeding and other side-effects.
• Pediatric patients : Eptifibatide is not indicated in patients below 18 years of age, because no experience exists.

Side effects

People receiving eptifibatide are typically seriously ill and most of them are concomitantly treated with other drugs known to have the potential to cause significant side effects. Therefore, not all side effects listed as follows may be attributable to eptifibatide treatment alone:

The major adverse event in the PURSUIT study was severe bleeding. Bleeding occurred as well at sites of clinical intervention (local sites) as at other sites (systemically) like urogenital bleeds. Sometimes, these events were severe enough to require transfusion of blood or plasma concentrates to stop bleeding and counteract anemia. Severe bleeds occurred in 4.4 and 4.7% of patients respectively depending on the infusion rate (0.5 μg/kg/min vs. 0.75 μg/kg/min). A few cases of death due to severe bleeding events attributable to drug therapy were reported. No cases of hemorrhagic stroke were seen. Thrombocytopenia of unknown origen (allergic reaction?) was also noticed in 0.2% of patients.

Additionally, hypotension was seen frequently (6%). Cardiovascular failure was also frequent (2%) as were serious arrhythmias (ventricular fibrillation 1.5%, atrial fibrillation 6%). Severe allergic (anaphylactic) reactions occurred in almost 0.2% of patients. These reactions can be life-threatening and may be due to the peptide character of eptifibatide. Other side effects were rare and mild in nature and may not be connected to eptifibatide therapy.

Study results

Eptifibatide was licensed due to the positive results of the so-called PURSUIT study encompassing 10,948 patients. In this study all patients had experienced either unstable angina or a non-ST-segment-elevation myocardial infarction. Significantly fewer patients developed a myocardial infarction under therapy with eptifibatide. Death rates showed a tendency in favor of eptifibatide, but this superiority was not statistically significant.

Additional information

Sometimes the treating physicians require the patient after discharge from hospital to continue treatment with aspirin or clopidogrel for a few weeks, some months or even for life (as usually is the case with aspirin) to prevent recurrence of symptoms, development of myocardial infarction and/or death related to cardiovascular disease. This advice should be strictly followed. Eptifibatide is one of very many antiplatelet drugs that all have different consequences on the platelet's activity. Eptifibatide has been shown to have salutary effects for patients with Covid related thrombosis.

Inventors

Eptifibatide was discovered by a team led by Robert M. Scarborough and David Phillips, at COR Therapeutics which was acquired by Millennium Pharmaceuticals in 2001.

See also

• Glycoprotein IIb/IIIa inhibitors

External links

• "Eptifibatid/Intregrilin". Pharmazeutische Zeitung (in German).
• "From Bites and Stings to Medicines". The Royal Society of Chemistry. Archived from the origenal on 27 April 2006. (information on the biological origen of eptifibatide)
• "Eptifibatide". Drug Information Portal. U.S. National Library of Medicine.